Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.

Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%.

In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.

Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins.

In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.

The latest trading day saw Boston Scientific (BSX) settling at $45.6, representing a +2.86% change from its previous close.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.

Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Sell-side analysts remain relatively upbeat on the stock.

Boston Scientific has experienced a ~53% collapse over twelve months, driven by guidance cuts, WATCHMAN deceleration, EP share loss, and a mixed CHAMPION-AF readout. FY26 guidance was cut to 6.5-8.0% organic growth and $3.34-$3.41 EPS, with management tempering long-term 10%+ growth expectations. BSX trades at a significant discount to peers (12.6x FY27E P/E), despite maintaining a robust ~8% revenue and ~10-11% EPS growth profile.